

CITATION REPORT

List of articles citing

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target

DOI: 10.1093/annonc/mdn169
Annals of Oncology, 2008, 19, 1523-9.

Source: <https://exaly.com/paper-pdf/44311461/citation-report.pdf>

Version: 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
832	Clinicopathological characteristics and predictive markers of early gastric cancer with recurrence. 2009 , 24, 1158-64		28
831	A review of in vitro and in vivo models of oesophageal and gastric cancer. 2009 , 4, 1267-79		
830	Explanatory approach for evaluation of machine learning-induced knowledge. 2009 , 37, 1543-51		4
829	Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents. 2009 , 8, 3015-23		45
828	Emerging role of capecitabine in gastric cancer. 2009 , 29, 318-30		13
827	Identification of novel hub genes associated with liver metastasis of gastric cancer. 2009 , 125, 2844-53		54
826	Expression of anion exchanger 1 is associated with tumor progress in human gastric cancer. 2009 , 135, 1323-30		22
825	Nature meets nurture: molecular genetics of gastric cancer. 2009 , 126, 615-28		176
824	Author reply to the letter to the Editor Robotic D2 surgery for gastric cancer. 2009 , 23, 1922-1923		
823	Recommendations on current approach to gastric cancer. 2009 , 11, 518-25		3
822	Clinical relevance associated to the analysis of circulating tumour cells in patients with solid tumours. 2009 , 11, 659-68		4
821	Micropapillary carcinoma of stomach: a clinicopathologic and immunohistochemical study of 11 cases. 2010 , 34, 1139-46		39
820	Down-regulation of human epidermal growth factor receptor 2/neu oncogene by corosolic acid induces cell cycle arrest and apoptosis in NCI-N87 human gastric cancer cells. 2010 , 33, 931-7		27
819	Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. 2010 , 17, 14-7		93
818	Genetic and epigenetic alteration in gastric carcinogenesis. 2010 , 15 Suppl 1, 34-9		60
817	Palliative resection in noncurative gastric cancer patients. 2010 , 34, 1015-21		28
816	[Grayzone lymphoma. Clinical relevance]. 2010 , 31, 42-9		

815	Determination de HER2 dans les adélocarcinomes pour établir le pronostic et prédire la réponse aux traitements. 2010 , 12, 416-421	
814	Increased mRNA expression of epidermal growth factor receptor, human epidermal receptor, and survivin in human gastric cancer after the surgical stress of laparotomy versus carbon dioxide pneumoperitoneum in a murine model. 2010 , 24, 1427-33	8
813	Determination de HER2 dans les adélocarcinomes pour établir le pronostic et prédire la réponse aux traitements. 2010 , 36, 30-35	
812	Activation of AMP-activated protein kinase on human gastric cancer cells by apoptosis induced by corosolic acid isolated from <i>Weigela subsessilis</i> . 2010 , 24, 1857-61	20
811	Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification. 2010 , 9, 1198-207	32
810	Host genetic variants in the IGF binding protein-3 impact on survival of patients with advanced gastric cancer treated with palliative chemotherapy. 2010 , 11, 1247-56	5
809	Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. 2010 , 16, 1509-19	164
808	Novel biomarkers of metastatic cancer. 2010 , 10, 581-90	12
807	Lack of HER2 overexpression and amplification in small intestinal adenocarcinoma. 2010 , 134, 880-5	12
806	Recent advances in gastrointestinal oncology--updates and insights from the 2009 annual meeting of the American society of clinical oncology. 2010 , 3, 11	28
805	Pathological complete response after neoadjuvant chemotherapy with trastuzumab-containing regimen in gastric cancer: a case report. 2010 , 3, 31	22
804	Trastuzumab: in HER2-positive metastatic gastric cancer. 2010 , 70, 2259-67	26
803	Dysregulation of cellular signaling in gastric cancer. 2010 , 295, 144-53	131
802	Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. 2010 , 376, 687-97	4587
801	Classification of HER2/neu status in gastric cancer using a breast-cancer derived proteome classifier. 2010 , 9, 6317-22	63
800	Trastuzumab in HER2-positive metastatic gastric cancer: profile report. 2011 , 25, 257-9	1
799	MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab. 2011 , 17, 2725-33	206
798	Anti-HER agents in gastric cancer: from bench to bedside. 2011 , 8, 369-83	61

797	Gastric metastasis of breast cancer: a single centre retrospective study. 2011 , 43, 823-7	34
796	Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization. 2011 , 135, 1460-5	57
795	Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma. 2011 , 12, 2493-503	16
794	Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. 2011 , 306, 171-9	122
793	What is the reference cytotoxic regimen for advanced gastric cancer: standard versus optimal therapy?. 2011 , 11, 1843-50	
792	New developments in the treatment of metastatic gastric cancer: focus on trastuzumab. 2011 , 4, 21-6	12
791	HER-2 Evaluation in a Specific Gastric Cancer Population with the Highest Rate of Mortality in Spain. 2011 , 2011, 391564	10
790	Her-2/neu testing and therapy in gastroesophageal adenocarcinoma. 2010 , 2011, 674182	30
789	How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer?. 2011 , 23, 396-402	21
788	HER2 testing in gastric and gastroesophageal junction cancers: a new therapeutic target and diagnostic challenge. 2011 , 19, 506-8	25
787	Variation in human genetic polymorphisms, their association with Helicobacter pylori acquisition and gastric cancer in a multi-ethnic country. 2011 , 26, 1725-32	21
786	Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections. 2011 , 59, 832-40	91
785	Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. 2011 , 104, 1372-6	122
784	The effect of direct translocation across endosomes on the cytotoxicity of the recombinant protein e23sFv-Fdt-casp6 to HER2 positive gastric cancer cells. 2011 , 32, 7641-50	10
783	Genomic and epigenetic profiles of gastric cancer: potential diagnostic and therapeutic applications. 2011 , 41, 24-38	70
782	Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival. 2011 , 18, 2010-7	50
781	Decreased expression of RASSF6 is a novel independent prognostic marker of a worse outcome in gastric cancer patients after curative surgery. 2011 , 18, 3858-67	28
780	Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. 2011 , 18, 2833-40	115

779	Prognostic significance of HER2/neu expression in gastric cancer. 2011 , 123, 450-4	11
778	Relation between transforming growth factor- β expression, its receptor and clinicopathological factors and survival in HER2-negative gastric cancers. 2011 , 123, 668-73	12
777	Inflammation in gastric adenocarcinoma of the cardia: how do EBV infection, Her2 amplification and cancer progression influence tumor-infiltrating lymphocytes?. 2011 , 458, 403-11	19
776	Molecular targeted therapy in gastrointestinal cancer. 2011 , 10, 380-385	2
775	Predictive biomarker and clinicopathological characteristics analysis for recurrence of early gastric cancer. 2011 , 10, 394-398	
774	Low frequency of HER2 amplification and overexpression in early onset gastric cancer. 2011 , 34, 89-95	35
773	Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer. 2011 , 13, 179-84	67
772	SEOM clinical guidelines for using molecular markers in clinical practice. 2011 , 13, 587-91	
771	BRCA1 monoclonal antibody conjugated fluorescent magnetic nanoparticles for in vivo targeted magnetofluorescent imaging of gastric cancer. 2011 , 9, 23	50
770	Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation. 2011 , 24, 908-16	38
769	Changing pathology with changing drugs: tumors of the gastrointestinal tract. 2011 , 78, 76-89	13
768	Positive response to trastuzumab in a case of HER2-overexpressing metastatic gastric cancer that presented as severe thrombocytopenia. 2011 , 34, 621-4	3
767	Impact of HER-2 overexpression/amplification on the prognosis of gastric cancer patients undergoing resection: a single-center study of 1,036 patients. 2011 , 16, 1706-13	48
766	Trastuzumab: a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer. 2011 , 7, 187-99	22
765	Trastuzumab plus chemotherapy in gastric cancer overexpressing HER-2 and EGFR: a case report. 2011 , 34, 42-5	3
764	Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. 2011 , 29, 3030-6	198
763	Genomic and genetic alterations influence the progression of gastric cancer. 2011 , 17, 290-9	93
762	Targeted therapies and predictive markers in epithelial malignancies of the gastrointestinal tract. 2012 , 136, 496-503	7

761	Quantitation of HER2/neu expression in primary gastroesophageal adenocarcinomas using conventional light microscopy and quantitative image analysis. 2012 , 136, 610-7	17
760	Management of advanced gastric cancer. 2012 , 6, 199-208; quiz 209	61
759	HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications. 2012 , 136, 691-7	69
758	HER2 testing in gastric cancer: a practical approach. 2012 , 25, 637-50	386
757	Phase II multi-institutional prospective randomised trial comparing S-1+paclitaxel with S-1+cisplatin in patients with unresectable and/or recurrent advanced gastric cancer. 2012 , 107, 31-6	24
756	Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. 2012 , 18, 546-54	111
755	Immunohistochemical biomarkers in gastric cancer research and management. 2012 , 2012, 868645	9
754	Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer. 2012 , 46, 637-48	62
753	Gastric HER2 Testing Study (GaTHER): an evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia. 2012 , 36, 577-82	38
752	Putative tumor metastasis-associated genes in human gastric cancer. 2012 , 41, 1068-84	2
751	Cancer and the Use of Biosensors for Cancer Clinical Testing. 2012 , 3-40	1
750	HER2 testing in gastric and esophageal adenocarcinoma: new diagnostic challenges arising from new therapeutic options. 2012 , 87, 40-5	9
749	Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. 2012 , 18, 4910-8	321
748	Current status of targeted therapies in advanced gastric cancer. 2012 , 16 Suppl 2, S29-34	34
747	Mechanism of resistance to trastuzumab and molecular sensitization via ADCC activation by exogenous expression of HER2-extracellular domain in human cancer cells. 2012 , 61, 1905-16	21
746	HER2 expression in gastric cancer in Indian population--an immunohistochemistry and fluorescence in situ hybridization study. 2012 , 31, 106-10	18
745	Phase I and II clinical trials for gastric cancer. 2012 , 21, 113-28	3
744	A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. 2012 , 61, 673-84	476

743	Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?. 2012 , 43, 413-22	62
742	Human epithelial growth factor receptor 2 (HER2) status in primary and metastatic esophagogastric junction adenocarcinomas. 2012 , 43, 1206-12	29
741	HER2 monoclonal antibody conjugated RNase-A-associated CdTe quantum dots for targeted imaging and therapy of gastric cancer. 2012 , 33, 7093-102	67
740	Med19 promotes gastric cancer progression and cellular growth. 2012 , 504, 262-7	17
739	Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas. 2012 , 12, 569	30
738	Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models. 2012 , 10, 180	36
737	Gene therapy of malignant solid tumors by targeting erbB2 receptors and by activating T cells. 2012 , 27, 711-8	8
736	Gene Signatures in Gastric Cancer. 2012 , 95-113	
735	Approaching heterogeneity of human epidermal growth factor receptor 2 in surgical specimens of gastric cancer. 2012 , 43, 2070-9	25
734	Leptin and HER-2 are associated with gastric cancer progression and prognosis of patients. 2012 , 66, 419-24	16
733	Are biopsy specimens predictive of HER2 status in gastric cancer patients?. 2013 , 58, 397-404	29
732	Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial. 2012 , 10, 274	26
731	Adenoviral delivery of the EMX2 gene suppresses growth in human gastric cancer. 2012 , 7, e45970	13
730	Palliative und supportive Therapie beim Karzinom des Ösophagogastralen Übergangs. 2012 , 28, 121-127	
729	HER-2 expression in immunohistochemistry has no prognostic significance in gastric cancer patients. 2012 , 2012, 941259	31
728	Tumor size predicts survival in mucinous gastric carcinoma. 2012 , 106, 757-64	6
727	Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes--a systematic review. 2012 , 130, 2845-56	125
726	SEOM clinical guidelines for the diagnosis and treatment of gastric adenocarcinoma. 2012 , 14, 528-35	13

725	In vivo targeting of HER2-positive tumor using 2-helix affibody molecules. 2012 , 43, 405-13	9
724	mTOR as a therapeutic target in patients with gastric cancer. 2012 , 130, 491-6	72
723	Mesothelin expression correlates with prolonged patient survival in gastric cancer. 2012 , 105, 195-9	44
722	Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens. 2012 , 62, 221-8	82
721	Beclin 1 activation enhances chemosensitivity and predicts a favorable outcome for primary duodenal adenocarcinoma. 2013 , 34, 713-22	19
720	Gastric cancer pathology and underlying molecular mechanisms. 2013 , 30, 150-8	70
719	Design of a universal biointerface for sensitive, selective, and multiplex detection of biomarkers using surface plasmon resonance imaging. 2013 , 138, 6052-62	37
718	HER2 in gastric cancer: an immunohistochemical study on tissue microarrays and the corresponding whole-tissue sections with a supplemental fish study. 2013 , 19, 855-65	10
717	Immunohistochemical analysis of invasive micropapillary carcinoma pattern in four cases of gastric cancer. 2013 , 46, 114-21	19
716	Modern oncological approaches to gastric adenocarcinoma. 2013 , 42, 359-69	37
715	HER2 status for prognosis and prediction of treatment efficacy in adenocarcinomas: a review. 2013 , 88, 123-33	14
714	Molecular diagnostics in esophageal and gastric neoplasms. 2013 , 33, 867-73	6
713	The Reliability of Endoscopic Biopsies in Assessing HER2 Status in Gastric and Gastroesophageal Junction Cancer: A Study Comparing Biopsies with Surgical Samples. 2013 , 6, 10-6	38
712	Receptor-directed chimeric toxins created by sortase-mediated protein fusion. 2013 , 12, 2273-81	34
711	HER2 and lung cancer. 2013 , 13, 1219-28	50
710	A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors. 2013 , 15, R110	72
709	Molecular biomarkers in esophageal, gastric, and colorectal adenocarcinoma. 2013 , 140, 133-47	24
708	A large cohort of consecutive patients confirmed frequent HER2 positivity in gastric carcinomas with advanced stages. 2013 , 20 Suppl 3, S477-84	31

707	The evolving role of HER2 evaluation for diagnosis and clinical decision making for breast and gastric adenocarcinoma. 2013 , 88, 121-31	13
706	Targeting HER2-positive cancer cells with receptor-redirectioned anthrax protective antigen. 2013 , 7, 440-51	50
705	Clinical significance of intratumoral HER2 heterogeneity in gastric cancer. 2013 , 49, 1448-57	116
704	Current questions for the treatment of advanced gastric cancer. 2013 , 39, 60-7	133
703	Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines. 2013 , 138, 1-12	23
702	Recycling antimalarial leads for cancer: Antiproliferative properties of N-cinnamoyl chloroquine analogues. 2013 , 23, 6769-72	12
701	Hyaluronic acid receptor-targetable imidazolized nanovectors for induction of gastric cancer cell death by RNA interference. 2013 , 34, 4327-38	33
700	LGR5 is a biomarker for stratification of HER-2 positive breast cancer patients and personalized treatment. 2013 , 81, 439-42	3
699	Phosphorylation of 4E-BP1 predicts sensitivity to everolimus in gastric cancer cells. 2013 , 331, 220-9	19
698	The prognostic significance of p21 and Her-2 gene expression and mutation/polymorphism in patients with gastric adenocarcinoma. 2013 , 30, 357	10
697	Metastatic gastric cancer treatment: a little slow but worthy progress. 2013 , 30, 464	30
696	Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. 2013 , 14, 490-9	621
695	Genetics/genomics/proteomics of gastric adenocarcinoma. 2013 , 42, 241-60	16
694	Neoadjuvant chemotherapy for nonmetastatic esophago-gastric adenocarcinomas: a systematic review and meta-analysis. 2013 , 31, 421-31	11
693	Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment. 2013 , 16, 261-7	53
692	A phase II trial of trastuzumab combined with irinotecan in patients with advanced HER2-positive chemo-refractory gastric cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group OGS1203 (HERBIS-5). 2013 , 43, 838-40	14
691	'All action no talk': the role of HER2/neu in adjuvant therapy choice for gastric cancer. <i>Annals of Oncology</i> , 2013 , 24, 1715-1717	10.3 3
690	A clinical-biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status. <i>Annals of Oncology</i> , 2013 , 24, 693-701	10.3 50

689	HER2 status in advanced gastric carcinoma: A retrospective multicentric analysis from Sicily. 2013 , 6, 1591-1594	22
688	Y-box binding protein-1 contributes to both HER2/ErbB2 expression and lapatinib sensitivity in human gastric cancer cells. 2013 , 12, 737-46	27
687	Targeted therapy for gastric cancer--current status. 2013 , 19, 75-81	7
686	Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals. 2013 , 73, 2221-34	39
685	Esophageal carcinoma: are modern targeted therapies shaking the rock?. 2013 , 25, 417-24	9
684	The clinical relevance and prognostic significance of HER2/Neu in gastric cancers. 2013 , 33, 8-12	
683	Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer. 2013 , 12, 509-19	58
682	Combined HER2 analysis of biopsies and surgical specimens to optimize detection of trastuzumab-eligible patients in eso-gastric adenocarcinoma: a GERCOR study. <i>Annals of Oncology</i> , 2013 , 24, 3035-9	10.3 29
681	Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United States. 2013 , 12, 2261-72	17
680	Combined blockade of HER2 and VEGF exerts greater growth inhibition of HER2-overexpressing gastric cancer xenografts than individual blockade. 2013 , 45, e52	26
679	Clinical significance of vimentin expression and Her-2 status in patients with gastric carcinoma. 2013 , 6, 184-90	6
678	Expression and purification of a soluble ESX-binding core domain of SUR2. 2013 , 43, 364-75	0
677	Advances in biomarkers for esophageal cancer. 2013 , 13, 1169-80	5
676	Gastric cancer: past accomplishments, present approaches and future aspirations. 2013 , 10, 47-77	
675	HER-2 as a Prognostic and Predictive Biomarker in Cancer. 2013 , 77-120	
674	Suppression of FUT1 attenuates cell proliferation in the HER2-overexpressing cancer cell line NCI-N87. 2013 , 29, 13-20	21
673	HER2 therapies and gastric cancer: a step forward. 2013 , 19, 6165-9	35
672	Role of Notch signaling pathway in gastric cancer pathogenesis. 2013 , 17, 1-5	24

671	Human epidermal growth factor receptor-2 overexpression and amplification in metastatic and recurrent high grade or type 2 endometrial carcinomas. 2013 , 6, 1065-71	1
670	MET amplification as a potential therapeutic target in gastric cancer. 2013 , 4, 9-17	73
669	HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer. 2013 , 8, e61565	32
668	Serum HER 2 extracellular domain level is correlated with tissue HER 2 status in metastatic gastric or gastro-oesophageal junction adenocarcinoma. 2013 , 8, e63458	5
667	Ribonucleotide reductase large subunit M1 predicts poor survival due to modulation of proliferative and invasive ability of gastric cancer. 2013 , 8, e70191	15
666	Therapeutic effect of human iPS-cell-derived myeloid cells expressing IFN- γ against peritoneally disseminated cancer in xenograft models. 2013 , 8, e67567	28
665	Chemotherapy for advanced gastric cancer: review and update of current practices. 2013 , 7, 385-93	47
664	EGFR, HER-2 and KRAS in canine gastric epithelial tumors: a potential human model?. 2014 , 9, e85388	26
663	Efficacy and Safety of Trastuzumab-based Therapy in Combination with Different Chemotherapeutic Regimens in Advanced Esophagogastric Cancer in a Single Cancer-center Experience. 2014 , 100, 237-242	3
662	Synthetic genistein glycosides inhibiting EGFR phosphorylation enhance the effect of radiation in HCT 116 colon cancer cells. 2014 , 19, 18558-73	23
661	Assessment and prognostic analysis of EGFR, HER2, and HER3 protein expression in surgically resected gastric adenocarcinomas. 2015 , 8, 7-14	17
660	Comparison of HER2 status by fluorescence in situ hybridisation and immunohistochemistry in gastric cancer. 2014 , 18, 95-9	2
659	New directions in perioperative management of locally advanced esophagogastric cancer. 2014 , e172-8	6
658	How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer. 2014 , 19, 1046-55	17
657	IMP3 expression in gastric cancer: association with clinicopathological features and HER2 status. 2014 , 140, 2163-8	15
656	Multi-colour FISH in oesophageal adenocarcinoma-predictors of prognosis independent of stage and grade. 2014 , 110, 2985-95	12
655	HER2 in solid tumors: more than 10 years under the microscope; where are we now?. 2014 , 10, 1469-86	31
654	Gastroesophageal heterotopia and HER2/neu overexpression in an adenocarcinoma arising from a small bowel duplication. 2014 , 138, 428-31	1

653	[Pertuzumab and solid tumors: perspectives]. 2014 , 101, 1114-21	2
652	HER2 in resected gastric cancer: Is there prognostic value?. 2014 , 109, 61-6	24
651	Positron emission tomography imaging with 18F-labeled ZHER2:2891 affibody for detection of HER2 expression and pharmacodynamic response to HER2-modulating therapies. 2014 , 20, 1632-43	28
650	HER2 and GATA4 are new prognostic factors for early-stage ovarian granulosa cell tumor-a long-term follow-up study. 2014 , 3, 526-36	24
649	Comparison of immunohistochemistry, four in situ hybridization methods and quantitative polymerase chain reaction for the molecular diagnosis of HER2 status in gastric cancer: a study of 55 cases. 2014 , 10, 2669-74	8
648	Therapy of peritoneally disseminated colon cancer by TAP-deficient embryonic stem cell-derived macrophages in allogeneic recipients. 2014 , 193, 2024-33	11
647	Prognosis significance of HER2 status and TACC1 expression in patients with gastric carcinoma. 2014 , 31, 280	5
646	Trastuzumab and oxaliplatin exhibit a synergistic antitumor effect in HER2-positive gastric cancer cells. 2014 , 25, 315-22	11
645	HER2 expression and PI3K-Akt pathway alterations in gastric cancer. 2014 , 89, 12-7	52
644	MEK inhibitor for gastric cancer with MEK1 gene mutations. 2014 , 13, 3098-106	15
643	Prognostic impact of the c-MET polymorphism on the clinical outcome in locoregional gastric cancer patients. 2014 , 24, 588-96	8
642	Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer. 2014 , 20, 4559-73	53
641	Importance of HER2 Work-Up and Treatment Even in Patients with Poor Performance Status: A Case Report. 2014 , 2014, 731581	
640	Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. 2014 , 2014, 852748	439
639	Unraveling trastuzumab and lapatinib inefficiency in gastric cancer: Future steps (Review). 2014 , 2, 175-181	40
638	Detection of Her-2/neu expression in gastric cancer: Quantitative PCR versus immunohistochemistry. 2014 , 8, 1501-1507	9
637	Human epidermal growth factor receptor 2 testing in gastric cancer: recommendations of an Asia-Pacific task force. 2014 , 10, 297-307	32
636	The safety of concentrated trastuzumab in 100 ml of saline solution for administration to patients with HER2-positive breast cancer: a phase 1 study. 2014 , 60, 1-6	3

635	Adoptive antitumor immunotherapy in vitro and in vivo using genetically activated erbB2-specific T cells. 2014 , 37, 351-9	8
634	Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer. 2014 , 33, 3334-41	87
633	Prognostic value of HER-2/neu expression in epithelial ovarian cancer: a meta-analysis. 2014 , 35, 33-8	5
632	HER2 expression in carcinomas of the true cardia (Siewert type II esophagogastric junction carcinoma). 2014 , 38, 426-30	6
631	Effects of a human compact anti-ErbB2 antibody on gastric cancer. 2014 , 17, 107-15	6
630	Prognostic value of epidermal growth factor receptors in gastric cancer: a survival analysis by Weibull model incorporating long-term survivors. 2014 , 17, 76-86	31
629	The siRNA cocktail targeting VEGF and HER2 inhibition on the proliferation and induced apoptosis of gastric cancer cell. 2014 , 386, 117-24	19
628	Prognostic significance of HER2 expression based on trastuzumab for gastric cancer (ToGA) criteria in gastric cancer: an updated meta-analysis. 2014 , 35, 5315-21	30
627	Population pharmacokinetics and exposure-response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer. 2014 , 73, 737-47	75
626	FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation. 2014 , 464, 145-56	41
625	High-level copy number gains of established and potential drug target genes in gastric cancer as a lead for treatment development and selection. 2014 , 37, 41-52	11
624	Biomarkers for gastric cancer: prognostic, predictive or targets of therapy?. 2014 , 464, 367-78	132
623	Human epidermal growth factor receptor-2 expression in primary and metastatic gastric cancer. 2014 , 19, 303-11	19
622	The microRNA-21/PTEN pathway regulates the sensitivity of HER2-positive gastric cancer cells to trastuzumab. 2014 , 21, 343-50	75
621	Biomarkers of drugs targeting HER-family signalling in cancer. 2014 , 232, 219-29	47
620	HER2 amplification and overexpression are significantly correlated in mucinous epithelial ovarian cancer. 2014 , 45, 810-6	16
619	The current status of neoadjuvant therapy for esophageal cancer. 2014 , 26, 102-9	8
618	Establishment and characterization of esophageal squamous cell carcinoma patient-derived xenograft mouse models for preclinical drug discovery. 2014 , 94, 917-26	26

617	Innovative personalized medicine in gastric cancer: time to move forward. 2014 , 86, 37-43	17
616	Mutually exclusive FGFR2, HER2, and KRAS gene amplifications in gastric cancer revealed by multicolour FISH. 2014 , 353, 167-75	42
615	[Standards for diagnostics and therapy of gastric cancer]. 2014 , 55, 925-41	
614	The role of HER3 in gastric cancer. 2014 , 68, 809-12	16
613	HER-2 overexpression and survival in colorectal cancer: a meta-analysis. 2014 , 15, 582-9	8
612	Clinicopathological and prognostic significance of HER2 overexpression in gastric cancer: a meta-analysis of the literature. 2014 , 35, 4849-58	39
611	HER2 expression in primary gastric cancers and paired synchronous lymph node and liver metastases. A possible road to target HER2 with radionuclides. 2014 , 35, 6319-26	5
610	Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer. 2014 , 13, 92	705
609	BRCAA1 antibody- and Her2 antibody-conjugated amphiphilic polymer engineered CdSe/ZnS quantum dots for targeted imaging of gastric cancer. 2014 , 9, 244	30
608	New approach to cancer therapy based on a molecularly defined cancer classification. 2014 , 64, 70-4	20
607	A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond. 2014 , 351, 30-40	50
606	The effect of Helicobacter pylori CagA on the HER-2 copy number and expression in gastric cancer. 2014 , 546, 288-96	6
605	Targeted therapy for gastric cancer: molecular pathways and ongoing investigations. 2014 , 1846, 232-7	53
604	Treatment options in patients with metastatic gastric cancer: current status and future perspectives. 2014 , 20, 3905-15	67
603	The role of tumour microenvironment in gastric cancer angiogenesis. 2014 , 9, 325-8	8
602	Prognostic role of lemur tyrosine kinase 3 in postoperative gastric cancer. 2014 , 2, 756-760	9
601	Prognostic significance of the co-overexpression of fibroblast growth factor receptors 1, 2 and 4 in gastric cancer. 2014 , 2, 509-517	44
600	Tissue-Based Companion Diagnostics: Development of IHC Assays from an Industry Perspective. 2014 , 281-304	

599	Conference Scene: Fighting a smarter war against cancer. 2014 , 3, 131-133	1
598	Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer. 2015 , 15, 894	21
597	Concordance of HER2 expression in paired primary and metastatic sites of gastric and gastro-oesophageal junction cancers. 2015 , 47, 641-6	8
596	HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a distinct subset of patients for dual inhibition therapy. 2015 , 136, 1629-35	28
595	The impact of concomitant genomic alterations on treatment outcome for trastuzumab therapy in HER2-positive gastric cancer. 2015 , 5, 9289	33
594	A concordant expression pattern of fatty acid synthase and membranous human epidermal growth factor receptor 2 exists in gastric cancer and is associated with a poor prognosis in gastric adenocarcinoma patients. 2015 , 10, 2107-2117	6
593	GLRecruitment systems specifically select PPI and affinity-enhanced candidate proteins that interact with membrane protein targets. 2015 , 5, 16723	2
592	The clinical significance of HER2 protein amplification/expression in urinary bladder lesion. 2015 , 13, 146-52	9
591	Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer. 2015 , 34, 132	27
590	HER2 testing in malignant effusions of metastatic gastric carcinoma: is it feasible?. 2015 , 43, 80-5	17
589	Gefitinib in definitive management of esophageal or gastroesophageal junction cancer: a retrospective analysis of two clinical trials. 2015 , 28, 547-51	3
588	Expression of Human Epidermal Growth Factor Receptor-2 in Resected Rectal Cancer. 2015 , 94, e2106	6
587	Polymorphisms of Tumor Necrosis Factor Alpha in Moroccan Patients with Gastric Pathology: New Single-Nucleotide Polymorphisms in TNF- β (-193) (G/A). 2015 , 2015, 143941	11
586	Treatment for unresectable gastric cancer. 2015 , 58, 209	1
585	Recent advances in the HER2 targeted therapy of gastric cancer. 2015 , 3, 42-51	32
584	Targets and optimization of antibody specificity. 2015 , 90-104	
583	PRR11 Is a Prognostic Marker and Potential Oncogene in Patients with Gastric Cancer. 2015 , 10, e0128943	25
582	HIF-1 β Induces Multidrug Resistance in Gastric Cancer Cells by Inducing MiR-27a. 2015 , 10, e0132746	38

581	Acquisition of resistance to trastuzumab in gastric cancer cells is associated with activation of IL-6/STAT3/Jagged-1/Notch positive feedback loop. 2015 , 6, 5072-87	74
580	HER2 Status in Premalignant, Early, and Advanced Neoplastic Lesions of the Stomach. 2015 , 2015, 234851	20
579	HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. 2015 , 18, 476-84	262
578	Biomarkers for personalized medicine in GI cancers. 2015 , 45, 14-27	9
577	Histopathologic characteristics of gastric adenocarcinoma in Mexican patients: A 10-year experience at the Hospital Juárez de México. 2015 , 80, 21-26	2
576	Clinical significance of assessing Her2/neu expression in gastric cancer with dual tumor tissue paraffin blocks. 2015 , 46, 850-7	23
575	Addition of all-trans-retinoic acid to omeprazole and sucralfate therapy improves the prognosis of gastric dysplasia. 2015 , 43, 204-16	10
574	Overexpression of HOXA10 promotes gastric cancer cells proliferation and HOXA10(+)/CD44(+) is potential prognostic biomarker for gastric cancer. 2015 , 94, 642-52	25
573	SNAPR: a bioinformatics pipeline for efficient and accurate RNA-seq alignment and analysis. 2015 , 1, 22-25	9
572	EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition. 2015 , 47, 499-505	11
571	The JAK/STAT signaling cascade in gastric carcinoma (Review). 2015 , 47, 1617-26	51
570	Upregulation of circulating cytokeratin 20, urokinase plasminogen activator and C-reactive protein is associated with poor prognosis in gastric cancer. 2015 , 3, 1213-1220	8
569	HER2 assessment by silver in situ hybridization: where are we now?. 2015 , 15, 385-98	5
568	HER2 amplification detected in the circulating DNA of patients with gastric cancer: a retrospective pilot study. 2015 , 18, 698-710	54
567	Serum HER2 levels and HER2 status in tumor cells in advanced gastric cancer patients. 2015 , 45, 43-8	7
566	HER2 expression in locally advanced gastric cancer with extensive lymph node (bulky N2 or paraaortic) metastasis (JCOG1005-A trial). 2015 , 18, 467-75	17
565	Erythropoietin-Producing Hepatocellular A1 is an Independent Prognostic Factor for Gastric Cancer. 2015 , 22, 2329-35	9
564	A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. 2015 , 33, 177-86	20

563	HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison. 2015 , 141, 1343-51	24
562	Overview of multimodal therapy for adenocarcinoma of the esophagogastric junction. 2015 , 63, 549-56	10
561	Trastuzumab Inhibits Growth of HER2-Negative Gastric Cancer Cells Through Gastrin-Initialized CCKBR Signaling. 2015 , 60, 3631-41	12
560	Molecular Mechanisms in Gastric Carcinogenesis. 2015 , 35-56	1
559	HER 2 Expression in Gastric and Gastro-esophageal Junction (GEJ) Adenocarcinomas. 2015 , 9, EC06-10	17
558	Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies. 2015 , 20, 499-507	56
557	Hurdles on the road to personalized medicine. 2015 , 9, 935-9	12
556	Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. 2015 , 51, 482-488	84
555	Human epidermal growth factor receptor-2 antibodies enhance the specificity and anticancer activity of light-sensitive doxorubicin-labeled liposomes. 2015 , 57, 1-11	35
554	Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study. 2015 , 102, 324-31	38
553	Tumor profiling of gastric and esophageal carcinoma reveal different treatment options. 2015 , 16, 764-9	16
552	Evaluation of Trastuzumab Anti-Tumor Efficacy and its Correlation with HER-2 Status in Patient-Derived Gastric Adenocarcinoma Xenograft Models. 2015 , 21, 947-55	7
551	Droplet digital PCR measurement of HER2 in patients with gastric cancer. 2015 , 112, 1652-5	57
550	Clinicopathological features and prognostic significance of HER2 expression in gastric cancer. 2015 , 88, 147-56	14
549	Oncogenic HER2 fusions in gastric cancer. 2015 , 13, 116	12
548	New targets in gastric cancer. 2015 , 8, 92-100	
547	Pathologic diagnostics of HER2 positivity in gastroesophageal adenocarcinoma. 2015 , 143, 257-64	14
546	PTEN deficiency as a predictive biomarker of resistance to HER2-targeted therapy in advanced gastric cancer. 2015 , 88, 76-85	24

545	Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival. 2015 , 68, 374-80	21
544	The HER2 gene and HER2 protein status and chromosome 17 polysomy in gastric cancer cells in own material. 2015 , 23, 113-7	4
543	Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer. 2015 , 76, 397-408	27
542	Clinical Significance of HER2 Overexpression in Gastric and Gastroesophageal Junction Cancers. 2015 , 19, 1565-71	9
541	Integrated Proteomic and Genomic Analysis of Gastric Cancer Patient Tissues. 2015 , 14, 4995-5006	6
540	A novel dual EGFR/HER2 inhibitor KU004 induces cell cycle arrest and apoptosis in HER2-overexpressing cancer cells. 2015 , 20, 1599-612	8
539	Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2). 2015 , 113, 716-21	12
538	Cancer Genetics and Implications for Clinical Management. 2015 , 95, 919-34	5
537	MicroRNA-induced drug resistance in gastric cancer. 2015 , 74, 191-9	45
536	Histopathologic characteristics of gastric adenocarcinoma in Mexican patients: a 10-year experience at the Hospital Juárez of Mexico. 2015 , 80, 21-6	6
535	Design, synthesis, and anticancer evaluation of long-chain alkoxyated mono-carbonyl analogues of curcumin. 2015 , 103, 44-55	18
534	A HER2-specific Modified Fc Fragment (Fcab) Induces Antitumor Effects Through Degradation of HER2 and Apoptosis. 2015 , 23, 1722-1733	23
533	Management of gastric cancer: East vs West. 2015 , 39, 315-41	7
532	Simultaneous detection of clinically relevant mutations and amplifications for routine cancer pathology. 2015 , 17, 10-8	33
531	In vivo molecular imaging of HER2 expression in a rat model of Barrett's esophagus adenocarcinoma. 2015 , 28, 394-403	19
530	HER2 Expression in Gastric and Gastroesophageal Cancer: Report from a Tertiary Care Hospital in North India. 2015 , 77, 447-51	8
529	Prognostic impact of venous invasion in stage IB node-negative gastric cancer. 2015 , 18, 297-305	27
528	The sensitivity of gastric cancer to trastuzumab is regulated by the miR-223/FBXW7 pathway. 2015 , 136, 1537-45	68

527	The coexpression and prognostic significance of c-MET, fibroblast growth factor receptor 2, and human epidermal growth factor receptor 2 in resected gastric cancer: a retrospective study. 2016 , 9, 5919-5929	9
526	HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice. 2016 , 22, 5879-87	57
525	Predictive biomarkers for targeted and cytotoxic agents in gastric cancer for personalized medicine. 2016 , 10, 171-80	6
524	Clinicopathological Significance and Diagnostic Accuracy of c-MET Expression by Immunohistochemistry in Gastric Cancer: A Meta-Analysis. 2016 , 16, 141-151	9
523	HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives. 2016 , 7, 69060-69074	21
522	Association of HER2 status with prognosis in gastric cancer patients undergoing R0 resection: A large-scale multicenter study in China. 2016 , 22, 5406-14	11
521	The genomics and therapeutics of HER2-positive gastric cancer-from trastuzumab and beyond. 2016 , 7, 750-762	35
520	Clinical applications of liquid biopsies in gastrointestinal oncology. 2016 , 7, 675-686	7
519	Prognostic Importance of Cell Cycle Regulators Cyclin D1 () and Cyclin-Dependent Kinase Inhibitor 1B (/p27) in Sporadic Gastric Cancers. 2016 , 2016, 9408190	3
518	Mucin-Type O-Glycosylation in Gastric Carcinogenesis. 2016 , 6,	27
517	Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. 2016 , 7, 49322-49333	643
516	EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus. 2016 , 16, 406	23
515	Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer. 2016 , 17,	24
514	Current and emerging therapies in unresectable and recurrent gastric cancer. 2016 , 22, 4812-23	40
513	Prognostic Value of KIF2A and HER2-Neu Overexpression in Patients With Epithelial Ovarian Cancer. 2016 , 95, e2803	18
512	[HER2 testing in gastric cancer : Results of a meeting of German experts]. 2016 , 37, 361-6	8
511	Discordant human epidermal growth factor receptor 2 overexpression in primary and metastatic upper gastrointestinal adenocarcinoma signifies poor prognosis. 2016 , 68, 230-40	15
510	Human epidermal growth factor receptor 2/neu as a novel therapeutic target in sinonasal undifferentiated carcinoma. 2016 , 38 Suppl 1, E1926-34	13

509	Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition. 2016 , 6, 20502	60
508	A long non-coding RNA signature to improve prognosis prediction of gastric cancer. 2016 , 15, 60	128
507	Metabolic Signature on 18F-FDG PET/CT, HER2 Status, and Survival in Gastric Adenocarcinomas. 2016 , 44, 234-238	4
506	HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. 2016 , 146, 647-669	30
505	Reduced phosphorylation of ribosomal protein S6 is associated with sensitivity to MEK inhibition in gastric cancer cells. 2016 , 107, 1919-1928	9
504	Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer. 2016 , 22, 2659-67	33
503	The ever-changing landscape of pancreatic cancer stem cells. 2016 , 16, 489-96	17
502	Personalised Treatment in Gastric Cancer: Myth or Reality?. 2016 , 18, 41	11
501	Targeted therapy in gastric cancer. 2016 , 48, 278-284	20
500	Clinical pathology of metastatic gastric carcinoma to the breast: A report of two cases and a review of literature. 2016 , 11, 3081-3084	7
499	Gastric cancer. 2016 , 388, 2654-2664	1152
498	Gastric biomarkers: a global review. 2016 , 14, 212	67
497	Clinical significance of NOTCH1 intracellular cytoplasmic domain translocation into the nucleus in gastric cancer. 2016 , 5, 344-348	5
496	Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancer. 2016 , 160, 29-40	45
495	HER2-targeted antibody drug conjugates for ovarian cancer therapy. 2016 , 93, 274-86	22
494	HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. 2016 , 140, 1345-1363	64
493	Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniques. 2016 , 16, 653	26
492	A HER2 selective theranostic agent for surgical resection guidance and photodynamic therapy. 2016 , 15, 1227-1238	12

491	Tyrosine Kinase Signaling Pathways in Normal and Cancer Cells. 2016 , 1-25	
490	Coronary vasculature patterning requires a novel endothelial ErbB2 holoreceptor. 2016 , 7, 12038	29
489	Concordance rate between HER2 immunohistochemistry and in situ hybridization in gastric carcinoma: systematic review and meta-analysis. 2016 , 31, e1-10	16
488	Personalisierte Medizin bei soliden Tumoren. 2016 , 28, 443-451	
487	Evodiamine sensitizes BGC-823 gastric cancer cells to radiotherapy in vitro and in vivo. 2016 , 14, 413-9	12
486	Intracranial hypertension as the primary symptom of gastric signet-ring cell carcinoma: A case report and literature review. 2016 , 95, e4687	4
485	A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer. 2016 , 15, 2251-8	5
484	The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer. 2016 , 380, 20-30	14
483	Molecular targeted photoimmunotherapy for HER2-positive human gastric cancer in combination with chemotherapy results in improved treatment outcomes through different cytotoxic mechanisms. 2016 , 16, 37	24
482	HER2-positive gastric cancer identified by serum HER2: A case report. 2016 , 11, 3575-3578	1
481	Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients. 2016 , 19, 183-91	79
480	Serum HER2 as an adjunct to assess HER2 status for advanced gastric cancer: A prospective multicenter trial (SHERLOCK). 2016 , 55, 309-17	6
479	Targeted Therapies for Advanced Oesophagogastric Cancer: Recent Progress and Future Directions. 2016 , 76, 13-26	7
478	Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples. 2016 , 100, 287-93	24
477	Relationship Between 18F-FDG PET/CT Findings and HER2 Expression in Gastric Cancer. 2016 , 57, 1040-4	30
476	Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin). 2016 , 142, 1231-7	10
475	A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer. 2016 , 77, 957-62	20
474	HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. 2016 , 238, 562-70	126

473	Reduced cohesin destabilizes high-level gene amplification by disrupting pre-replication complex bindings in human cancers with chromosomal instability. 2016 , 44, 558-72	15
472	The 100 most influential manuscripts in gastric cancer: A bibliometric analysis. 2016 , 28, 83-90	39
471	The over-expression of FGFR4 could influence the features of gastric cancer cells and inhibit the efficacy of PD173074 and 5-fluorouracil towards gastric cancer. 2016 , 37, 6881-91	8
470	Monoclonal antibodies for treating gastric cancer: promises and pitfalls. 2016 , 16, 759-69	6
469	Translating gastric cancer genomics into targeted therapies. 2016 , 100, 141-6	35
468	Phase II trial of dacomitinib in patients with HER2-positive gastric cancer. 2016 , 19, 1095-1103	26
467	MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy. 2016 , 19, 687-95	24
466	HER2 Expression in Gastric Adenocarcinoma-a Study in a Tertiary Care Centre in South India. 2016 , 7, 18-24	4
465	Prognostic significance of PAK4 expression in gastric cancer. 2016 , 69, 580-5	15
464	Targeting HER 2 and angiogenesis in gastric cancer. 2016 , 16, 111-22	14
463	HER2/ERBB2 immunoreactivity in human retinoblastoma. 2016 , 37, 6135-42	7
462	MET overexpression and amplification define a distinct molecular subgroup for targeted therapies in gastric cancer. 2016 , 19, 778-88	16
461	Clinicopathological Variation of Lauren Classification in Gastric Cancer. 2016 , 22, 197-202	109
460	MicroRNA-216b is Down-Regulated in Human Gastric Adenocarcinoma and Inhibits Proliferation and Cell Cycle Progression by Targeting Oncogene HDAC8. 2016 , 11, 197-207	18
459	Prognostic significance of human tissue kallikrein-related peptidases 11 and 15 in gastric cancer. 2016 , 37, 437-46	10
458	Metabolic landscape of advanced gastric cancer according to HER2 and its prognostic implications. 2016 , 19, 421-430	10
457	HER2 testing in paired biopsy and excision specimens of gastric cancer: the reliability of the scoring system and the clinicopathological factors relevant to discordance. 2016 , 19, 176-82	19
456	RHOA mutation in diffuse-type gastric cancer: a comparative clinicopathology analysis of 87 cases. 2016 , 19, 403-411	37

455	Clinicopathologic Characteristics of Patients with HER2 Insertions in Non-small Cell Lung Cancer. 2017 , 24, 291-297	17
454	Monitoring the HER2 copy number status in circulating tumor DNA by droplet digital PCR in patients with gastric cancer. 2017 , 20, 126-135	88
453	Impact of HER2 expression on outcome in gastric cancer patients with liver metastasis. 2017 , 19, 197-203	7
452	Genome-wide analysis of DNA copy number alterations in early and advanced gastric cancers. 2017 , 56, 527-537	14
451	HER2 Status in Gastric Cancer: Comparison between Primary and Distant Metastatic Disease. 2017 , 23, 55-61	10
450	Advanced gastric adenocarcinoma: optimizing therapy options. 2017 , 10, 263-271	16
449	HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. 2017 , 35, 446-464	176
448	Selection of DNA aptamers for extra cellular domain of human epidermal growth factor receptor 2 to detect HER2 positive carcinomas. 2017 , 19, 976-988	21
447	Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition. 2017 , 16, 1145-1154	33
446	HER2 as an Emerging Oncotarget for Colorectal Cancer Treatment After Failure of Anti-Epidermal Growth Factor Receptor Therapy. 2017 , 16, 247-251	21
445	Gastric cancer: somatic genetics as a guide to therapy. 2017 , 54, 305-312	57
444	Immunohistochemical analysis of PTEN, HER2/neu, and ki67 expression in patients with gastric cancer and their association with survival. 2017 , 24, 99-106	12
443	Cancer Genomics and Important Oncologic Mutations: A Contemporary Guide for Body Imagers. 2017 , 283, 314-340	12
442	Expression of pRb, Ki67 and HER 2/neu in gastric carcinomas: Relation to different histopathological grades and stages. 2017 , 30, 1-7	8
441	Down-regulated miRs specifically correlate with non-cardial gastric cancers and Lauren's classification system. 2017 , 116, 184-194	4
440	Gastric Cancer. 2017 , 397-408	1
439	Rationally co-targeting divergent pathways in KRAS wild-type colorectal cancers by CANScript technology reveals tumor dependence on Notch and Erbb2. 2017 , 7, 1502	17
438	High expression of EphA3 (erythropoietin-producing hepatocellular A3) in gastric cancer is associated with metastasis and poor survival. 2017 , 17, 8	14

437	MicroRNA-509-3p Inhibits Cancer Cell Proliferation and Migration via Upregulation of XIAP in Gastric Cancer Cells. 2017 , 25, 455-461	21
436	Human Epidermal Growth Factor Receptor-2 in Sri Lankan Gastric Carcinoma Patients with Clinicopathological Association and Survival. 2017 , 62, 2498-2510	1
435	The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature. 2017 , 15, 68	59
434	Distinct prognostic values of YAP1 in gastric cancer. 2017 , 39, 1010428317695926	16
433	SUMO-1 Gene Silencing Inhibits Proliferation and Promotes Apoptosis of Human Gastric Cancer SGC-7901 Cells. 2017 , 41, 987-998	11
432	HER2 testing in gastric cancer: results of a German expert meeting. 2017 , 143, 835-841	27
431	A potential pitfall in evaluating HER2 immunohistochemistry for gastric signet ring cell carcinomas. 2017 , 49, 38-43	9
430	Human epidermal growth factor receptor 2 status of gastric cancer patients in Asia: results from a large, multicountry study. 2017 , 13, 249-260	7
429	Correlation of Ki-67 Proliferative Antigen Expression and Tumor Response to Induction Chemotherapy Containing Cell Cycle-Specific Agents in Head and Neck Squamous Cell Carcinoma. 2017 , 11, 338-345	5
428	Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. 2017 , 18, 1512-1522	195
427	Detection of MET mRNA in gastric cancer in situ. Comparison with immunohistochemistry and sandwich immunoassays. 2017 , 92, 425-435	4
426	Quality standards in upper gastrointestinal endoscopy: a position statement of the British Society of Gastroenterology (BSG) and Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland (AUGIS). 2017 , 66, 1886-1899	134
425	HER2 testing in advanced gastric and gastro-oesophageal cancer: analysis of an Australia-wide testing program. 2017 , 49, 575-581	8
424	The relevance of gastric cancer biomarkers in prognosis and pre- and post- chemotherapy in clinical practice. 2017 , 95, 1082-1090	40
423	Will molecular target agents enable the multidisciplinary treatment in stage IV gastric cancer?. 2017 , 43, 1835-1845	3
422	Cyclin D1 overexpression correlates with poor tumor differentiation and prognosis in gastric cancer. 2017 , 14, 4517-4526	35
421	HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium. 2017 , 123, 4099-4105	85
420	DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. 2017 , 141, 1682-1689	69

419	MEG2 is regulated by miR-181a-5p and functions as a tumour suppressor gene to suppress the proliferation and migration of gastric cancer cells. 2017 , 16, 133	32
418	Genetically functionalized ferritin nanoparticles with a high-affinity protein binder for immunoassay and imaging. 2017 , 988, 81-88	11
417	In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer. 2017 , 114, E7301-E7310	53
416	High expression of P21-activated kinase 5 protein is associated with poor survival in gastric cancer. 2017 , 14, 404-410	9
415	Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial. 2017 , 3, 767-773	52
414	Detection of Her2-overexpressing cancer cells using keyhole shaped chamber array employing a magnetic droplet-handling system. 2017 , 93, 32-39	4
413	Genomic landscape of gastric cancer: molecular classification and potential targets. 2017 , 60, 126-137	13
412	Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer. 2017 , 20, 465-474	16
411	Vascular endothelial growth factor expression is an independent poor prognostic factor for human epidermal growth factor receptor 2 positive gastric cancer. 2017 , 208, 40-50	6
410	Label-Free Biosensors for Early Diagnosis of Cancer Based on G-Quadruplex and Isothermal Amplification. 2017 , 83-114	1
409	Current Targeted Therapies in HER2-Positive Gastric Adenocarcinoma. 2017 , 32, 351-363	13
408	Meta-analysis of prognostic role of Ki-67 labeling index in gastric carcinoma. 2017 , 32, e447-e453	3
407	Gene copy number variation and protein overexpression of EGFR and HER2 in distal extrahepatic cholangiocarcinoma. 2017 , 49, 582-588	11
406	Molecular Targeting Therapy for Gastric Cancer: Current Advances and Obstacles. 2017 ,	
405	Factores genéticos y epigenéticos del cáncer gástrico. 2017 , 39, 5-20	
404	Irinotecan and 5-fluorouracil-co-loaded, hyaluronic acid-modified layer-by-layer nanoparticles for targeted gastric carcinoma therapy. 2017 , 11, 2595-2604	31
403	Gastric Cancer Cell Glycosylation as a Modulator of the ErbB2 Oncogenic Receptor. 2017 , 18,	19
402	Diagnostic, Predictive, Prognostic, and Therapeutic Molecular Biomarkers in Third Millennium: A Breakthrough in Gastric Cancer. 2017 , 2017, 7869802	58

401	High levels of serum platelet-derived growth factor-AA and human epidermal growth factor receptor-2 are predictors of colorectal cancer liver metastasis. 2017 , 23, 1233-1240	8
400	Human Epidermal Growth Factor Receptor 2 Expression in Unresectable Gastric Cancers: Relationship with CT Characteristics. 2017 , 18, 809-820	8
399	MicroRNA-133a Inhibits Proliferation of Gastric Cancer Cells by Downregulating ERBB2 Expression. 2017 , 25, 1169-1176	18
398	Clinical Significance of p53 Protein Expression, Beta-catenin Expression and HER2 Expression for Epstein-Barr Virus-associated Gastric Cancer. 2017 , 53, 140-146	4
397	Impact of c-erbB-2 protein on 5-year survival rate of gastric cancer patients after surgery: a cohort study and meta-analysis. 2017 , 103, 249-254	9
396	Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence hybridization (FISH) to select the optimal patients for matched therapy?. 2017 , 8, 100863-100898	11
395	HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline Summary From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. 2017 , 13, 53-57	8
394	HER2/ Testing In 432 Consecutive Breast Cancer Cases using FISH and IHC - A Comparative Study. 2017 , 11, EC01-EC05	3
393	Genomic alterations of ERBB receptors in cancer: clinical implications. 2017 , 8, 114371-114392	62
392	Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment. 2017 , 8, 405-417	11
391	Does histology really influence gastric cancer prognosis?. 2017 , 8, 1026-1036	9
390	Clinicopathological features and endoscopic findings of HER2-positive gastric cancer. 2018 , 32, 3964-3971	7
389	Target Therapy for Esophageal Adenocarcinoma. 2018 , 1756, 51-65	2
388	Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications. 2018 , 472, 749-758	29
387	Ramucirumab in HER-2-positive gastroesophageal adenocarcinoma: an argument for overcoming trastuzumab resistance. 2018 , 14, 223-228	7
386	Correlation of trastuzumab-based treatment with clinical characteristics and prognosis in HER2-positive gastric and gastroesophageal junction cancer: A retrospective single center analysis. 2018 , 19, 169-174	12
385	A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab. 2018 , 81, 505-514	23
384	EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas. 2018 , 21, 731-741	7

383	Isolated breast metastasis from gastric cancer in a male patient. 2018 , 11, 138-144	
382	Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica. 2018 , 104, NP38-NP41	0
381	Blockade of ITGA2 Induces Apoptosis and Inhibits Cell Migration in Gastric Cancer. 2018 , 20, 10	35
380	Detection of HER2 amplification in formalin-fixed paraffin-embedded breast carcinoma tissue with digital PCR using two TFF3 sequences as internal reference. 2018 , 104, 235-238	3
379	Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab. 2018 , 23, 1092-1102	28
378	The HER4-YAP1 axis promotes trastuzumab resistance in HER2-positive gastric cancer by inducing epithelial and mesenchymal transition. 2018 , 37, 3022-3038	37
377	Autophagy flux inhibition augments gastric cancer resistance to the anti-human epidermal growth factor receptor 2 antibody trastuzumab. 2018 , 15, 4143-4150	3
376	Prevalence of HER2 Positivity and Its Clinicopathological Correlation in Locally Advanced/Metastatic Gastric Cancer Patients in Malaysia. 2018 , 49, 150-157	10
375	HER2 Status in Gastric and Gastroesophageal Junction Cancer: Results of the Large, Multinational HER-EAGLE Study. 2018 , 26, 239-245	18
374	Associations between early tumor shrinkage and depth of response and clinical outcomes in patients treated with 1st-line chemotherapy for advanced gastric cancer. 2018 , 21, 267-275	8
373	An independent survival prognostic role for human epidermal growth factor receptor 2 in gastric cancer: evidence from a meta-analysis. 2018 , 20, 212-220	4
372	Digital image analysis of HER2 immunohistochemistry in gastric- and oesophageal adenocarcinoma: a validation study on biopsies and surgical specimens. 2018 , 72, 191-200	10
371	In situ analysis of FGFR2 mRNA and comparison with FGFR2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients. 2018 , 21, 401-412	10
370	Molecular Diagnosis and Targeted Therapy for Gastric Cancer. 2018 , 63-80	
369	Chemotherapy for alpha-fetoprotein producing gastric cancers expressing human epidermal growth factor receptor 2. 2018 , 24, 298-301	2
368	Discovery of anilino-furo[2,3-d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity. 2018 , 144, 330-348	16
367	CUL4B promotes gastric cancer invasion and metastasis-involvement of upregulation of HER2. 2018 , 37, 1075-1085	23
366	HER2 Heterogeneity in Gastroesophageal Cancer Detected by Testing Biopsy and Resection Specimens. 2018 , 142, 516-522	10

365	Gastric Cancer: Recent Molecular Classification Advances, Racial Disparity, and Management Implications. 2018 , 14, 217-224	34
364	HER2 Positive Gastric Carcinomas and Their Clinico-Pathological Characteristics. 2018 , 6, 1187-1192	2
363	An updated association between TNF- β -238G/A polymorphism and gastric cancer susceptibility in East Asians. 2018 , 38,	4
362	New drug developments in metastatic gastric cancer. 2018 , 11, 1756284818808072	14
361	Examination of the expression and prognostic significance of DLGAPs in gastric cancer using the TCGA database and bioinformatic analysis. 2018 , 18, 5621-5629	4
360	Prognostic values of mRNA expression in human gastric cancer. 2018 , 38,	34
359	The Clinical and Biological Significance of Tyrosine Kinases in Gastric Cancer. 2018 , 29-56	1
358	Advances in molecular, genetic and immune signatures of gastric cancer: Are we ready to apply them in our patients' decision making?. 2018 , 10, 172-183	
357	Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604). 2018 , 105, 41-49	33
356	Changes in HER2 Expression and Amplification Status Following Preoperative Chemotherapy for Gastric Cancer. 2018 , 32, 1491-1498	5
355	Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8 T cells in the tumor microenvironment. 2018 , 6, 106	85
354	Clinical significance and biological roles of cyclins in gastric cancer. 2018 , 11, 6673-6685	14
353	Clinical Significance of Glycoprotein Non-metastatic B and Its Association with EGFR/HER2 in Gastrointestinal Cancer. 2018 , 9, 358-366	6
352	Biomarkers of gastric cancer: Current topics and future perspective. 2018 , 24, 2818-2832	162
351	Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. 2018 , 19, 1372-1384	193
350	Current status of immunotherapy and immune biomarkers in gastro-esophageal cancers. 2018 , 9, 196-207	13
349	Reduced expression of Rap1GAP as a prognostic biomarker for primary gastric cancer patients. 2018 , 22, 375-384	3
348	Correlation between HGF/c-Met and Notch1 signaling pathways in human gastric cancer cells. 2018 , 40, 294-302	10

347	MET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver metastasis. 2018 , 117, 1679-1686	11
346	Molecular Diagnostics in Esophageal and Gastric Neoplasms: 2018 Update. 2018 , 38, 357-365	6
345	Comparative analysis and optimization of protocols for producing recombinant lentivirus carrying the anti-Her2 chimeric antigen receptor gene. 2018 , 20, e3027	7
344	Current and future biomarkers in gastric cancer. 2018 , 103, 1688-1700	30
343	Evolving Treatment Strategies and Outcomes in Advanced Gastric Cancer with Peritoneal Metastasis. 2018 , 27, 519-537	19
342	Human Epidermal Growth Factor Receptor 2 Status in Gastric Carcinomas with Distinctive Prevalent Cribriform Component. 2018 , 2018, 1505428	3
341	Clinical Molecular Pathology. 2018 , 55-72	
340	Chemical Therapy. 2018 , 263-281	
339	When Tissue Is No Longer the Issue: Tissue-Agnostic Cancer Therapy Comes of Age. 2018 , 169, 233-239	15
338	The Clinical Landscape of Circulating Tumor DNA in Gastrointestinal Malignancies. 2018 , 8, 263	6
337	Proposed Molecular and miRNA Classification of Gastric Cancer. 2018 , 19,	40
336	Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions. 2018 , 18, 99	34
335	Polyethylene glycol-conjugated HER2-targeted peptides as a nuclear imaging probe for HER2-overexpressed gastric cancer detection in vivo. 2018 , 16, 168	11
334	Tumor targeting via EPR: Strategies to enhance patient responses. 2018 , 130, 17-38	618
333	DEAD-Box Protein RNA-Helicase DDX6 Regulates the Expression of HER2 and FGFR2 at the Post-Transcriptional Step in Gastric Cancer Cells. 2018 , 19,	13
332	Novel Systemic Therapies for Advanced Gastric Cancer. 2018 , 18, 1-19	25
331	HER2: An emerging target in colorectal cancer. 2018 , 42, 560-571	39
330	Prognostic Significance of Vascular Endothelial Growth Factor (VEGF) and Her-2 Protein in the Genesis of Cervical Carcinoma. 2018 , 6, 263-268	8

329	CT features of HER2-mutant lung adenocarcinomas. 2018 , 51, 279-283	7
328	Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment. 2018 , 13, e0198141	11
327	The clinical significance of platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) in gastric cancer: A systematic review and meta-analysis. 2018 , 127, 15-28	8
326	Prognostic value of the mRNA expression of gap junction β members in patients with gastric cancer. 2019 , 18, 1669-1678	4
325	Single-Cell Intravital Microscopy of Trastuzumab Quantifies Heterogeneous in vivo Kinetics. 2020 , 97, 528-539	10
324	Clinicopathological features and Borrmann classification associated with HER2-positive in primary gastric cancer. 2019 , 12, 287-294	3
323	A Novel Anti-HER2 Antibody-Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine. 2019 , 18, 1721-1730	29
322	Differential Effects of Purinergic Signaling in Gastric Cancer-Derived Cells Through P2Y and P2X Receptors. 2019 , 10, 612	14
321	Atovaquone: An Antiprotozoal Drug Suppresses Primary and Resistant Breast Tumor Growth by Inhibiting HER2/ β Catenin Signaling. 2019 , 18, 1708-1720	9
320	Differential expression of HER2 and downstream proteins in prediction of advanced tumor phenotypes and overall survival of patients with Epstein-Barr virus-positive vs. negative gastric cancers. 2019 , 215, 152675	3
319	Targeting β Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications. 2019 , 3,	7
318	Functional and Nonclinical Similarity of ABP 980, a Biosimilar of Trastuzumab. 2019 , 36, 177	8
317	Somatic mutation profiling and HER2 status in KRAS-positive Chinese colorectal cancer patients. 2019 , 9, 16894	4
316	Clinical and molecular prognostic markers of survival after surgery for gastric cancer: tumor-node-metastasis staging system and beyond. 2019 , 4, 59	7
315	HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer. 2019 , 18, 2135-2145	16
314	Impact of Specimen Type and Specimen Number on HER2 Status in Gastroesophageal Junction and Gastric Adenocarcinoma. 2019 , 151, 461-468	6
313	The promising role of monoclonal antibodies for gastric cancer treatment. 2019 , 11, 347-364	7
312	FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial. 2019 , 115, 97-106	15

311	TRP channels in gastric cancer: New hopes and clinical perspectives. 2019 , 82, 102053	7
310	A survival guide to HER2 testing in gastric/gastroesophageal junction carcinoma. 2019 , 90, 44-54	10
309	Multimodality management of locally advanced gastric cancer-the timing and extent of surgery. 2019 , 4, 42	6
308	Updates on Management of Gastric Cancer. 2019 , 21, 67	117
307	Temporal Modulation of HER2 Membrane Availability Increases Pertuzumab Uptake and Pretargeted Molecular Imaging of Gastric Tumors. 2019 , 60, 1569-1578	17
306	Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab. 2019 , 292, 171-179	23
305	From Molecular Classification to Targeted Therapy for Gastric Cancer in the Precision Medicine Era. 2019 , 155-172	
304	Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design. 2019 , 15, 2073-2082	30
303	Clinicopathologic Characteristics of HER2-positive Metastatic Colorectal Cancer and Detection of HER2 in Plasma Circulating Tumor DNA. 2019 , 18, 175-182	3
302	Nanomedicine in Gastric Cancer. 2019 , 213-247	
301	Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex. 2019 , 14, e0216095	14
300	A remarkable clinical response in advanced gastric cancer treated with trastuzumab plus capecitabine combination chemotherapy: A report of two cases. 2019 , 7, 714-718	1
299	Feasibility and clinical value of circulating tumor DNA testing in patients with gastric adenocarcinomas. 2019 , 10, 400-406	8
298	Bioinformatic exploration of OLFML2B overexpression in gastric cancer base on multiple analyzing tools. 2019 , 19, 227	13
297	EPHA2 blockade reverses acquired resistance to afatinib induced by EPHA2-mediated MAPK pathway activation in gastric cancer cells and avatar mice. 2019 , 145, 2440-2449	11
296	Synthetic miR-143 Inhibits Growth of HER2-Positive Gastric Cancer Cells by Suppressing KRAS Networks Including DDX6 RNA Helicase. 2019 , 20,	14
295	A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer. 2019 , 22, 1206-1214	17
294	Strategy for treatment of stage IV human epidermal growth factor 2-positive gastric cancer: a case report. 2019 , 13, 42	1

293	Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer. 2019 , 120, 522-526	8
292	Survival and prognostic factors in patients with gastrointestinal cancers and brain metastases: have we made progress?. 2019 , 208, 63-72	7
291	Durable Clinical Response to Pyrotinib After Resistance to Prior Anti-HER2 Therapy for HER2-Positive Advanced Gastric Cancer: A Case Report. 2019 , 9, 1453	12
290	HER2-specific chimeric antigen receptor-engineered natural killer cells combined with apatinib for the treatment of gastric cancer. 2019 , 106, 946-958	11
289	Epidermal Growth Factor Receptor Family and its Role in Gastric Cancer. 2019 , 9, 1308	40
288	Trastuzumab Specific Epitope Evaluation as a Predictive and Prognostic Biomarker in Gastric Cancer Patients. 2019 , 9,	3
287	Identification of an Activating Mutation in the Extracellular Domain of HER2 Conferring Resistance to Pertuzumab. 2019 , 12, 11597-11608	4
286	Significance of HER2 and Ki-67 in Preneoplastic Lesions and Carcinoma of Gallbladder. 2019 , 50, 848-854	4
285	Discovery of new quinazoline derivatives as irreversible dual EGFR/HER2 inhibitors and their anticancer activities - Part 1. 2019 , 29, 591-596	26
284	Mechanism of action of the trastuzumab biosimilar CT-P6. 2019 , 19, 1085-1095	6
283	High expression of ALPPL2 is associated with poor prognosis in gastric cancer. 2019 , 86, 49-56	6
282	MET is overexpressed in microsatellite instability-high gastric carcinoma. 2019 , 215, 433-438	3
281	Genome-wide analysis of ETV1 targets: Insights into the role of ETV1 in tumor progression. 2019 , 120, 8983-8991	2
280	Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models. 2019 , 11, 153-165	6
279	Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer. 2019 , 22, 518-525	17
278	Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer. 2019 , 83, 501-508	5
277	Prognostic values of inhibitory B kinases mRNA expression in human gastric cancer. 2019 , 39,	5
276	Cancer neovasculature-targeted near-infrared photoimmunotherapy (NIR-PIT) for gastric cancer: different mechanisms of phototoxicity compared to cell membrane-targeted NIR-PIT. 2020 , 23, 82-94	13

275	ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer. 2020 , 473, 156-163	16
274	CMIP promotes Herceptin resistance of HER2 positive gastric cancer cells. 2020 , 216, 152776	3
273	68Ga-ZHER2 PET/CT Reveals HER2-Positive Metastatic Gastric Cancer With Better Image Quality Than 18F-FDG. 2020 , 45, e101-e102	0
272	Integrated Microfluidic Device for Accurate Extracellular Vesicle Quantification and Protein Markers Analysis Directly from Human Whole Blood. 2020 , 92, 1574-1581	30
271	Ketamine exhibits anti-gastric cancer activity via induction of apoptosis and attenuation of PI3K/Akt/mTOR. 2020 , 16, 1140-1149	5
270	Trastuzumab in combination with paclitaxel enhances antitumor activity by promoting apoptosis in human epidermal growth factor receptor 2-positive trastuzumab-resistant gastric cancer xenograft models. 2020 , 31, 241-250	1
269	The Role of HER2 in Self-Renewal, Invasion, and Tumorigenicity of Gastric Cancer Stem Cells. 2020 , 10, 1608	1
268	Expression and significance of Her2 and Ki-67 in gastric adenocarcinoma without distant metastasis: a cohort study. 2020 , 20, 343	0
267	Preparation and characterization of antibody-drug conjugates acting on HER2-positive cancer cells. 2020 , 15, e0239813	2
266	Intratumoral and intertumoral heterogeneity of HER2 immunohistochemical expression in gastric cancer. 2020 , 216, 153229	3
265	The Third Generation Anti-HER2 Chimeric Antigen Receptor Mouse T Cells Alone or Together With Anti-PD1 Antibody Inhibits the Growth of Mouse Breast Tumor Cells Expressing HER2 and in Immune Competent Mice. 2020 , 10, 1143	11
264	Increased HOXC6 mRNA expression is a novel biomarker of gastric cancer. 2020 , 15, e0236811	3
263	Antibody-drug conjugates to treat gastric cancer. 2021 , 21, 923-930	2
262	Pyrotinib combined with CDK4/6 inhibitor in HER2-positive metastatic gastric cancer: A promising strategy from AVATAR mouse to patients. 2020 , 10, e148	6
261	Targeted Molecular Therapies in the Treatment of Esophageal Adenocarcinoma, Are We There Yet?. 2020 , 12,	1
260	Genomic Strategies for Personalized Cancer Therapy. 2020 , 1-60	
259	Gastric Cancer Heterogeneity and Clinical Outcomes. 2020 , 19, 1533033820935477	7
258	PD-L1 and HER2 Expression in Gastroesophageal Cancer: a Matched Case Control Study. 2020 , 26, 2225-2235	3

257	Gastrointestinal cancers: current biomarkers in esophageal and gastric adenocarcinoma. 2020 , 5, 55	9
256	Semiconducting quantum dots: Modification and applications in biomedical science. 2020 , 63, 1631-1650	12
255	Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies. 2020 , 21,	164
254	Comparative analysis of HER2 copy number between plasma and tissue samples in gastric cancer using droplet digital PCR. 2020 , 10, 4177	7
253	Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study). 2020 , 38, 1919-1927	49
252	HER2 as a potential biomarker of lymph node metastasis in undifferentiated early gastric cancer. 2020 , 10, 5270	5
251	ARPP-19 Mediates Herceptin Resistance via Regulation of CD44 in Gastric Cancer. 2020 , 13, 6629-6643	1
250	HER2 in Colorectal Carcinoma: Are We There yet?. 2020 , 13, 485-502	10
249	HER2 genomic heterogeneity is a frequent event in gastroesophageal adenocarcinoma and correlates with tumor morphology. 2020 , 216, 153090	1
248	TfR1 binding with H-ferritin nanocarrier achieves prognostic diagnosis and enhances the therapeutic efficacy in clinical gastric cancer. 2020 , 11, 92	24
247	Identification of targeted therapy options for gastric adenocarcinoma by comprehensive analysis of genomic data. 2020 , 23, 627-638	6
246	Human Epidermal Growth Factor Receptor 2 (HER2) in Advanced Gastric Cancer: Current Knowledge and Future Perspectives. 2020 , 80, 401-415	28
245	Upregulation of lncRNA SUMO1P3 promotes proliferation, invasion and drug resistance in gastric cancer through interacting with the CNBP protein.. 2020 , 10, 6006-6016	2
244	A systematical comparison of anti-angiogenesis and anti-cancer efficacy of ramucirumab, apatinib, regorafenib and cabozantinib in zebrafish model. 2020 , 247, 117402	15
243	Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance. 2020 , 12,	29
242	Transformable peptide nanoparticles arrest HER2 signalling and cause cancer cell death in vivo. 2020 , 15, 145-153	77
241	Molecular Classification of Gastric Cancer among Alaska Native People. 2020 , 12,	9
240	Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study. 2020 , 23, 579-590	7

239	C1GALT1 is associated with poor survival and promotes soluble Ephrin A1-mediated cell migration through activation of EPHA2 in gastric cancer. 2020 , 39, 2724-2740	10
238	Viennese risk prediction score for Advanced Gastroesophageal carcinoma based on Alarm Symptoms (VAGAS score): characterisation of alarm symptoms in advanced gastro-oesophageal cancer and its correlation with outcome. 2020 , 5,	2
237	Targeting HER2 Alterations in Non-Small-Cell Lung Cancer: A Comprehensive Review.. 2020 , 4, 411-425	31
236	Clinical Practice Observation of Trastuzumab in Patients with Human Epidermal Growth Receptor 2-Positive Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. 2020 , 25, e1181-e1187	8
235	CT Radiomics for Distinction of Human Epidermal Growth Factor Receptor 2 Negative Gastric Cancer. 2021 , 28, e86-e92	4
234	Impact of Ga-NOTA-MAL-MZHER2 PET imaging in advanced gastric cancer patients and therapeutic response monitoring. 2021 , 48, 161-175	8
233	Effectiveness of Trastuzumab in Routine Clinical Practice: A Population-based Study of Patients with HER-2-positive Oesophageal, Gastroesophageal and Gastric Cancer. 2021 , 33, 202-207	4
232	Clinical development of CAR T cell therapy in China: 2020 update. 2021 , 18, 792-804	19
231	Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays. 2021 , 34, 603-612	4
230	RNF43: A Biomarker With Potential Ramifications for Therapeutic Intervention in Gastric Cancer. 2021 , 11, 1202-1203	2
229	Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer. 2021 , 13, 1758835920986518	4
228	Evaluation of Near-infrared Fluorescence-conjugated Peptides for Visualization of Human Epidermal Receptor 2-overexpressed Gastric Cancer. 2021 , 21, 191-202	0
227	Esophageal Cancer. 2021 , 1813-1828	
226	Autophagy Blockade Limits HER2+ Breast Cancer Tumorigenesis by Perturbing HER2 Trafficking and Promoting Release Via Small Extracellular Vesicles. 2021 , 56, 341-355.e5	7
225	A narrative review: depth of response as a predictor of the long-term outcomes for solid tumors.. 2021 , 10, 1119-1130	0
224	Molecular Oncology in Management of Colorectal Cancer. 2021 , 12, 169-180	
223	Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial. 2021 , 145, 158-167	9
222	Comparative investigation of early-onset gastric cancer. 2021 , 21, 374	1

221	Development of a Novel Weighted Ranking Method for Immunohistochemical Quantification of a Heterogeneously Expressed Protein in Gastro-Esophageal Cancers. 2021 , 13,	
220	WEE1 inhibition reverses trastuzumab resistance in HER2-positive cancers. 2021 , 24, 1003-1020	3
219	Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective. 2021 , 24, 567-576	3
218	Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand?. 2021 , 24, 765-779	4
217	Where to Start and What to Do Next: The Sequencing of Treatments in Metastatic Esophagogastric Cancer. 2021 , 41, 1-16	1
216	PTEN is a predictive biomarker of trastuzumab resistance and prognostic factor in HER2-overexpressing gastroesophageal adenocarcinoma. 2021 , 11, 9013	1
215	Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer. 2021 , 19, 184	3
214	Differentiation and Regulation of T Cells: A Balancing Act for Cancer Immunotherapy. 2021 , 12, 669474	16
213	Near Infrared Photoimmunotherapy; A Review of Targets for Cancer Therapy. 2021 , 13,	12
212	Her2-Positive and Microsatellite Instability Status in Gastric Cancer-Clinicopathological Implications. 2021 , 11,	5
211	UCP-2 inhibitor enhanced the efficacy of trastuzumab against HER2 positive breast cancer cells. 2021 , 88, 633-642	3
210	The Pyroptosis-Related Signature Predicts Prognosis and Indicates Immune Microenvironment Infiltration in Gastric Cancer. 2021 , 9, 676485	47
209	A Reliable and Standardizable Differential PCR and qPCR Methodology Assesses HER2 Gene Amplification in Gastric Cancer. 2021 , 10,	
208	Life after Cell Death-Survival and Survivorship Following Chemotherapy. 2021 , 13,	1
207	Early B-cell factors involve in the tumorigenesis and predict the overall survival of gastric cancer. 2021 , 41,	1
206	Trimodality Approach for Esophageal Malignancies. 2021 , 101, 453-465	1
205	Immune-Related Nine-MicroRNA Signature for Predicting the Prognosis of Gastric Cancer. 2021 , 12, 690598	0
204	KRT18 Modulates Alternative Splicing of Genes Involved in Proliferation and Apoptosis Processes in Both Gastric Cancer Cells and Clinical Samples. 2021 , 12, 635429	0

203	Precision medicine: Uses and challenges. 2021 , 77, 258-265	0
202	Recent Advances in Systemic Treatments for HER-2 Positive Advanced Gastric Cancer. 2021 , 14, 4149-4162	6
201	A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer. 2021 , 21, 923	2
200	Development of a Novel Anti-HER2 Monoclonal Antibody HMab-181 for Gastric Cancer. 2021 , 40, 168-176	1
199	Treatment Patterns and Outcomes in Chinese Patients with Gastric Cancer by HER2 Status: A Noninterventional Registry Study (EVIDENCE). 2021 , 26, e1567-e1580	2
198	Regulation of follistatin-like 3 expression by miR-486-5p modulates gastric cancer cell proliferation, migration and tumor progression. 2021 , 13, 20302-20318	2
197	Precise Targeting Therapy of Orthotopic Gastric Carcinoma by siRNA and Chemotherapeutic Drug Codelivered in pH-Sensitive Nano Platform. 2021 , 10, e2100966	2
196	Increased expression levels of AURKA and KIFC1 are promising predictors of progression and poor survival associated with gastric cancer. 2021 , 224, 153524	1
195	Immunotherapy in Gastroesophageal Cancers: Current Evidence and Ongoing Trials. 2021 , 22, 100	0
194	The promise of bispecific antibodies: Clinical applications and challenges. 2021 , 99, 102240	9
193	Molecular Pathology of Gastroesophageal Cancer. 2021 , 14, 443-453	1
192	Combination treatment with trastuzumab and crizotinib in metastatic gastric cancer harboring Her-2 amplification and c-MET amplification: A case report. 2021 , 100, e27017	
191	Trastuzumab deruxtecan and other HER2-targeting agents for the treatment of HER2-positive gastric cancer. 2021 , 21, 1193-1201	2
190	Identification of tyrosine kinase inhibitors from Panax 'bipinnatifidus' and 'Panax pseudoginseng for RTK-HER2 and VEGFR2 receptors, by in silico approach. 2021 , 1	1
189	MTA2 sensitizes gastric cancer cells to PARP inhibition by induction of DNA replication stress. 2021 , 14, 101167	1
188	MULTIFACTOR ANALYSIS OF THE ONCOPROTEINS EXPRESSION DEPENDENCE IN GASTRIC CANCER. 2021 , 17, 079	
187	Feasibility of HER2-Targeted Therapy in Advanced Biliary Tract Cancer: A Prospective Pilot Study of Trastuzumab Biosimilar in Combination with Gemcitabine Plus Cisplatin. 2021 , 13,	7
186	Effect of Additional Trastuzumab in Neoadjuvant and Adjuvant Treatment for Patients with Resectable HER2-Positive Gastric Cancer. 2021 , 28, 4413-4422	2

185	Esophageal Cancer. 2012 , 571-579	1
184	Applications of tissue microarray technology. 2010 , 664, 1-16	15
183	Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas. 2013 , 26, 677-84	61
182	Does Specimen Type Have an Impact on HER2 Status in Endometrial Serous Carcinoma? Discordant HER2 Status of Paired Endometrial Biopsy and Hysterectomy Specimens in the Presence of Frequent Intratumoral Heterogeneity. 2021 , 40, 263-271	5
181	High Expression of Serine Hydroxymethyltransferase 2 Indicates Poor Prognosis of Gastric Cancer Patients. 2019 , 25, 7430-7438	9
180	The combination of RAD001 and MK-2206 exerts synergistic cytotoxic effects against PTEN mutant gastric cancer cells: involvement of MAPK-dependent autophagic, but not apoptotic cell death pathway. 2014 , 9, e85116	32
179	HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression. 2014 , 9, e98528	110
178	Tumor Content Chart-Assisted HER2/CEP17 Digital PCR Analysis of Gastric Cancer Biopsy Specimens. 2016 , 11, e0154430	5
177	Peri-operative chemotherapy in patients with oesophageal and gastro-oesophageal junction cancer - three years of experience. 2013 , 114, 57-71	2
176	HER2 Oncogene Amplification and Immunohistochemical Profiling in Gastric Adenocarcinoma. 2018 , 6, e83	2
175	Human epidermal growth factor receptor 2 (HER-2) status evaluation in advanced gastric cancer using immunohistochemistry versus silver in situ hybridization. 2017 , 17, 109-113	4
174	HBXIP promotes gastric cancer METTL3-mediated MYC mRNA m6A modification. 2020 , 12, 24967-24982	17
173	Importance of the type I insulin-like growth factor receptor in HER2, FGFR2 and MET-unamplified gastric cancer with and without Ras pathway activation. 2016 , 7, 54445-54462	9
172	JWA down-regulates HER2 expression via c-Cbl and induces lapatinib resistance in human gastric cancer cells. 2016 , 7, 71790-71801	6
171	Tumor suppressor role of miR-3622b-5p in ERBB2-positive cancer. 2017 , 8, 23008-23019	12
170	Quantitative proteomics profiling reveals activation of mTOR pathway in trastuzumab resistance. 2017 , 8, 45793-45806	19
169	Enhanced antiproliferative activity of antibody-functionalized polymeric nanoparticles for targeted delivery of anti-miR-21 to HER2 positive gastric cancer. 2017 , 8, 67189-67202	17
168	Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expression. 2014 , 5, 8317-29	48

167	GRAM domain-containing protein 1B (GRAMD1B), a novel component of the JAK/STAT signaling pathway, functions in gastric carcinogenesis. 2017 , 8, 115370-115383	8
166	Using antibody directed phototherapy to target oesophageal adenocarcinoma with heterogeneous HER2 expression. 2018 , 9, 22945-22959	7
165	Lipolysis-stimulated lipoprotein receptor overexpression is a novel predictor of poor clinical prognosis and a potential therapeutic target in gastric cancer. 2018 , 9, 32917-32928	9
164	Epstein-Barr virus latent membrane protein 2A suppresses the expression of HER2 via a pathway involving TWIST and YB-1 in Epstein-Barr virus-associated gastric carcinomas. 2015 , 6, 207-20	20
163	AMP-activated kinase (AMPK) regulates activity of HER2 and EGFR in breast cancer. 2015 , 6, 14754-65	21
162	Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer. 2016 , 7, 4925-38	25
161	AT101 exerts a synergetic efficacy in gastric cancer patients with 5-FU based treatment through promoting apoptosis and autophagy. 2016 , 7, 34430-41	17
160	A CT-based radiomics nomogram for prediction of human epidermal growth factor receptor 2 status in patients with gastric cancer. 2020 , 32, 62-71	6
159	Advances in the Development of Anticancer HSP-based Vaccines. 2019 , 26, 427-445	4
158	Molecular Signaling in Tumorigenesis of Gastric Cancer. 2018 , 22, 217-30	20
157	Prevalence of HER2 Expression and Its Correlation with Clinicopathological Parameters in Gastric or Gastroesophageal Junction Adenocarcinoma in North-East Indian Population. 2019 , 20, 1139-1145	6
156	HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes. 2020 , 13,	9
155	Human epidermal growth factor receptor-2 in oesophageal cancers: an observational study. 2012 , 18, 6447-51; discussion p.6450	2
154	Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer. 2012 , 18, 6577-86	60
153	High mobility group-box 3 overexpression is associated with poor prognosis of resected gastric adenocarcinoma. 2012 , 18, 7319-26	18
152	Fibroblast growth factor receptor 4 Gly388Arg polymorphism in Chinese gastric cancer patients. 2013 , 19, 4568-75	14
151	Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapies. 2013 , 19, 6383-97	21
150	Lower serum folate is associated with development and invasiveness of gastric cancer. 2014 , 20, 11313-20	18

149	Proteomic and metabolic prediction of response to therapy in gastric cancer. 2014 , 20, 13648-57	18
148	Molecular targeting to treat gastric cancer. 2014 , 20, 13741-55	20
147	Expression of pyruvate dehydrogenase is an independent prognostic marker in gastric cancer. 2015 , 21, 5336-44	8
146	Companion diagnostics for the targeted therapy of gastric cancer. 2015 , 21, 10948-55	9
145	Metastatic gastric cancer treatment: Second line and beyond. 2016 , 22, 3069-77	21
144	Changing strategies for target therapy in gastric cancer. 2016 , 22, 1179-89	29
143	HER2-induced metastasis is mediated by AKT/JNK/EMT signaling pathway in gastric cancer. 2016 , 22, 9141-9153	21
142	Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer. 2017 , 23, 7407-7414	9
141	Chromogenic Hybridization Technique versus Immunohistochemistry in Assessment of HER2/neu Status in 448 Iraqi Patients with Invasive Breast Carcinoma. 2019 , 7, 1917-1925	1
140	Significant function and research progress of biomarkers in gastric cancer. 2020 , 19, 17-29	13
139	Identification of circulating tumor DNA using a targeted 545-gene next generation sequencing panel in patients with gastric cancer. 2020 , 19, 2251-2257	2
138	Pyrotinib enhances the radiosensitivity of HER2-overexpressing gastric and breast cancer cells. 2020 , 44, 2634-2644	9
137	Gastric cancer: Classification, histology and application of molecular pathology. 2012 , 3, 251-61	281
136	The prognostic value of UHRF-1 and p53 in gastric cancer. 2016 , 22, 25-9	5
135	Gastric cancer review. 2014 , 13, 14	157
134	HER2Status in Gastric Adenocarcinomas Assessed by Immunohistochemistry, Automated Silver-Enhanced In Situ Hybridization and Fluorescence In Situ Hybridization. 2010 , 44, 493	2
133	FOXO1 Suppression is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells Through MET Upregulation. 2018 , 50, 239-254	22
132	Results and implications of the Trastuzumab for Gastric Cancer (ToGA) trial. 2011 , 1, 87-95	3

131	Precision medicine in gastric cancer. 2019 , 11, 804-829	40
130	Advancements and challenges in treating advanced gastric cancer in the West. 2019 , 11, 652-664	15
129	Gastric cancer: The times they are a-changin'. 2015 , 7, 303-16	13
128	Molecular classifications of gastric cancers: Novel insights and possible future applications. 2017 , 9, 194-208	38
127	Gastric stem cells and gastric cancer stem cells. 2013 , 46, 8-18	32
126	Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric Cancer. 2019 , 19, 375-392	6
125	Immunohistochemical Expression of Ki67 and HER2 in Colorectal Cancer Compared to Adenomatous and Normal Samples. 2017 , 10,	2
124	Developing Pathology Measures for the Quality Payment Program-Part II: Overcoming Challenges With Data Capture to Maximize Reimbursement. 2020 , 144, 697-705	1
123	Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. 2019 , 17, 855-883	267
122	Epidermal growth factor receptor gene polymorphisms and gastric cancer in Iran. 2013 , 14, 3187-90	5
121	Evaluation of HER-2/neu overexpression in gastric carcinoma using a tissue microarray. 2014 , 15, 7597-602	9
120	HER2 expression in ovarian mucinous carcinomas in Tunisia. 2014 , 15, 8121-5	4
119	Survey of Her2-neu Expression and its Correlation with Histology of Gastric Carcinoma and Gastroesophageal Junction Adenocarcinoma. 2015 , 16, 7755-8	4
118	Identifying multiple collagen gene family members as potential gastric cancer biomarkers using integrated bioinformatics analysis. 2020 , 8, e9123	13
117	Target Therapy and Immunotherapy in Gastric Cancer. 2021 , 225-233	
116	An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2-Antibody-Drug Conjugate against Refractory HER2-Positive Cancers. 2021 , 8, e2102414	2
115	The Value of Predicting Human Epidermal Growth Factor Receptor 2 Status in Adenocarcinoma of the Esophagogastric Junction on CT-Based Radiomics Nomogram. 2021 , 11, 707686	0
114	Single-cell atlas of lineage states, tumor microenvironment and subtype-specific expression programs in gastric cancer. 2021 ,	9

- 113 Antibody drug conjugates in gastrointestinal cancer: From lab to clinical development. **2021**, 340, 1-34 1
- 112 Genetische Aberration, Genexpressionprofile und Epigenetik. **2010**, 67-75
- 111 Molecular Mechanisms and Pathology of Gastric Carcinogenesis: Sporadic Cancers. **2013**, 67-81
- 110 Targeted Therapies and Molecular Diagnostics of Gastrointestinal Cancers. **2013**, 33-41
- 109 Using Genomic Biomarkers to Predict Patient Prognosis and Treatment Response in Gastric Cancer. **2013**, 105-136 0
- 108 Indications et gestion des effets secondaires. **2013**, 243-257
- 107 Signal Transduction Inhibitors of the HER Family. **2013**, 17-50
- 106 Distal esophageal tumors. **2013**, 196-210
- 105 Magenkarzinom. **2014**, 1-11
- 104 Development of a Mass Spectrometric Method for Pharmacokinetic Study of Trastuzumab. **2014**, 35, 1845-1847
- 103 Neoplasia of the Gastrointestinal Tract. 587-616
- 102 Molecular Markers in the Prediction of Response to Neoadjuvant Treatments in Esophagogastric Junction Adenocarcinoma. **2017**, 85-94
- 101 Human epidermal growth factor receptor 2 expression in gastric cancer patients treated with curative intent gastrectomy. **2017**, 13, 25-31
- 100 Assessment the of Amplification HER-2/neu Gene by Chromogenic In Situ Hybridization (CISH) Compared to Immunohistochemistry (IHC) Method in Gastric Cancer. **2018**, 6,
- 99 Human epidermal growth factor 2 status in gastric adenocarcinoma. **2018**, 38, 126-130
- 98 The synergistic antitumor effect of combined Anti-Human Epidermal Growth Factor Receptor 2 (HER2) antibody and Gamma Interferon therapy to Ab resistant breast cancer cells.
- 97 The Synergistic Antitumor Effect of Combined Anti-Human Epidermal Growth Factor Receptor 2 Antibody and Gamma Interferon Therapy on Antibody-resistant Breast Cancer Cells. **2019**, 31, 237-252
- 96 In situ analysis of Her2 DNA and RNA in retinoblastoma and adjacent retina. **2019**, 6, 357-366

- 95 GEFT protein expression in digestive tract malignant tumors and its clinical significance. **2019**, 18, 5577-5590 2
- 94 Detection of circulating tumor cells (CTCs) in cerebrospinal fluid of a patient with HER2-overexpressing gastric cancer and single cell analysis of intra-patient heterogeneity of CTCs.. **2019**, 8, 2107-2112
- 93 Esophageal and Gastric Cancer. **2020**, 31-46
- 92 Recent Development in the Biomarkers for the Gastric Cancer. **2020**, 115-138
- 91 HER-2 positivity is a high risk of recurrence of stage I gastric cancer. **2021**, 36, 1327-1337 1
- 90 Drug Targets for Biologics. **2020**, 71-88
- 89 Esophageal Cancer. **2020**, 1-16
- 88 Genetic Marker Identification for the Detection of Early-Onset Gastric Cancer Through Genome-Wide Association Studies. **2020**, 191-211
- 87 Actualizaci3n en c3ncer g3strico. **2020**, 13, 117-125
- 86 HER2-Positive Gastric Carcinoma Completely Resected after Chemotherapy. **2020**, 53, 213-220 1
- 85 Cancer genomic medicine in Japan. **2020**, 96, 316-321 5
- 84 Prognostic benefit of conversion surgery for HER2 positive stage IV gastric cancer; a case series study of eleven patients treated with trastuzumab-based chemotherapy. **2020**, 6, 219 2
- 83 Study of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Gastric Carcinoma. **2020**, 7, 2747-2751
- 82 HER2 discordance between paired primary gastric cancer and metastasis: a meta-analysis. **2015**, 27, 163-71 16
- 81 Refining docetaxel-containing therapy for gastric cancer. **2011**, 4, 96-105 3
- 80 HER-2/neu Marker Examination using Immunohistochemical Method in Patients Suffering from Gastric Adenocarcinoma. **2013**, 2, 199-203 5
- 79 AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel. **2014**, 7, 1449-58 23
- 78 HER4 is a novel prognostic biomarker in gastrointestinal stromal tumor specifically originated from stomach. **2014**, 4, 838-49 2

77	Up-regulation of ECT2 is associated with poor prognosis in gastric cancer patients. 2014 , 7, 8724-31	16
76	Downregulation of annexin A7 decreases proliferation, migration, and invasion of gastric cancer cells by reducing matrix metalloproteinase 1 and 9 expression. 2019 , 11, 2754-2764	6
75	Novel Biomarkers of Gastric Adenocarcinoma: Current Research and Future Perspectives. 2021 , 13,	3
74	Long-Term Efficacy of Neoadjuvant Concurrent Chemoradiotherapy for Potentially Resectable Advanced Siewert Type II and III Adenocarcinomas of the Esophagogastric Junction. 2021 , 11, 756440	0
73	Stomach: The Standard of Care – HER2. 2021 ,	
72	Emerging HER2-directed therapeutic agents for gastric cancer in early phase clinical trials.. 2022 ,	3
71	Current status and future perspectives in HER2 positive advanced gastric cancer.. 2022 , 1	3
70	Gastrointestinal System Cancers. 2022 , 411-461	
69	The drugs screened by OncoVee-Mini-PDX have significantly benefited the patient with HER2-positive advanced gastric cancer.. 2022 , 10781552221074973	0
68	PET imaging of gastric cancer. 2022 ,	
67	HER2 Positivity Is Affected by the Papillary Structure and Has a Bidirectional Prognostic Value for Gallbladder Carcinoma.. 2021 , 12, 831318	
66	Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective.. 2022 , 12, 780716	1
65	Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.. 2022 , 20, 167-192	37
64	The treatment of resectable gastric cancer: a literature review of an evolving landscape.. 2022 , 13, 871-884	0
63	Evaluation of Epidermal Growth Factor Receptor 2 Status in Gastric Cancer by Computer Tomography-Based Deep Learning Radiomics Nomogram.	
62	A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells.. 2022 ,	8
61	Gastric Cancer: Mechanisms, Biomarkers, and Therapeutic Approaches.. 2022 , 10,	1
60	Artificial intelligence to identify genetic alterations in conventional histopathology.. 2022 ,	1

59	Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer: A Review.. 2022,	4
58	Multicellular Modelling of Difficult-to-Treat Gastrointestinal Cancers: Current Possibilities and Challenges.. 2022, 23,	
57	OSgc: A Web Portal to Assess the Performance of Prognostic Biomarkers in Gastric Cancer.. 2022, 12, 856988	
56	Collagen Family and Other Matrix Remodeling Proteins Identified by Bioinformatics Analysis as Hub Genes Involved in Gastric Cancer Progression and Prognosis.. 2022, 23,	0
55	Epitope Mapping of an Anti-HER2 Monoclonal Antibody (HMab-181) Using Enzyme-Linked Immunosorbent Assay.. 2021, 40, 255-260	0
54	Molecular Pathogenesis, Targeted Therapies, and Future Perspectives for Gastric Cancer.. 2021,	4
53	High Frequency of Juxtamembrane Domain Mutation in Gastric Cancer.. 2022, 19, 105-112	0
52	A recombinant adenovirus fiber knob protein sensitizes gastric cancer cells to trastuzumab. 2019,	
51	An overview of the preclinical discovery and development of trastuzumab deruxtecan: a novel gastric cancer therapeutic.. 2022, 1-10	1
50	Real-World Data of Trastuzumab Deruxtecan for Advanced Gastric Cancer: A Multi-Institutional Retrospective Study.. 2022, 11,	0
49	KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer.. 2022, 1	0
48	Image_1.tif. 2020,	
47	Table_1.docx. 2020,	
46	DataSheet_1.pdf. 2019,	
45	Putative Clinical Potential of Amplification Assessment by ddPCR in FFPE-DNA and cfDNA of Gastroesophageal Adenocarcinoma Patients.. 2022, 14,	0
44	A prognostic scoring system for conversion surgery after trastuzumab-based chemotherapy for human epidermal growth factor receptor 2-positive advanced gastric cancer.. 2022, 1	
43	Association between HER2 heterogeneity and clinical outcomes of HER2-positive gastric cancer patients treated with trastuzumab.. 2022,	1
42	Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer.. 2022,	0

41	Molecular pathogenesis and emerging targets of gastric adenocarcinoma.. 2022 , 125, 1079-1095	1
40	HER2 in Colorectal Cancer: The Long and Winding Road From Negative Predictive Factor to Positive Actionable Target.. 2022 , 42, 1-14	0
39	Prospective analysis of the expression status of FGFR2 and HER2 in colorectal and gastric cancer populations: DS-Screen Study.. 2022 ,	0
38	Separation and Single-Cell Analysis for Free Gastric Cancer Cells in Ascites and Peritoneal Lavages Based on Microfluidic Chips.	
37	Resistance Mechanisms to HER2-Targeted Therapy in Gastroesophageal Adenocarcinoma: A Systematic Review. 2022 , 102418	1
36	Evaluation of Epidermal Growth Factor Receptor 2 Status in Gastric Cancer by CT-Based Deep Learning Radiomics Nomogram. 12,	0
35	The Durable Effect of Pyrotinib Plus Trastuzumab and Chemotherapy in HER2-Positive Gastric Cancer With Brain Metastases: A Case Report and Literature Review. 12,	0
34	Characteristics of gut microbiota in patients with gastric cancer by surgery, chemotherapy and lymph node metastasis.	1
33	Targeting the complexity of ERBB2 biology in gastroesophageal carcinoma. 2022 ,	0
32	An auristatin-based peptide-drug conjugate targeting Kita-Kyushu lung cancer antigen 1 for precision chemoradiotherapy in gastric cancer. 2022 , 241, 114617	
31	HER2 protein expression correlates with Lauren classification and P53 in gastric cancer patients. 2022 , 101, e30647	0
30	Effects of <i>Alkanna bracteosa</i> extract on the expression level of HSP90 α and HER2 genes in human gastric cancer cell line.	0
29	Landscape of exitrons in gastric cancer. 2022 , 84, 104272	0
28	European-Australasian consensus on the management of advanced gastric and gastro-oesophageal junction cancer: current practice and new directions. 2022 , 14, 175883592211188	0
27	Fifty years of progress in gastric cancer. 2022 , 126, 865-871	0
26	Aptamer-siRNA chimeras: Promising tools for targeting HER2 signaling in cancer.	0
25	Molecular and clinicopathological characteristics of ERBB2 gene fusions in 32,131 Chinese patients with solid tumors. 12,	0
24	Molecular Pathology of Gastric Cancer. 2022 , 22, 264	0

- 23 Signaling pathways and therapeutic interventions in gastric cancer. **2022**, 7, 0
- 22 Long-term follow-up of HER2 overexpression in patients with rectal cancer after preoperative radiotherapy: A prospective cohort study. 14, 2048-2060 0
- 21 The Perioperative and Operative Management of Esophageal and Gastric Cancer. **2022**, 1
- 20 Metabolism-associated molecular classification of gastric adenocarcinoma. 12, 0
- 19 Prognostic and clinical significance of HER-2 low expression in early-stage gastric cancer. **2022**, 22, 1
- 18 Artificial intelligence in gastric cancer: applications and challenges. **2022**, 10, 0
- 17 Recent advances in the progress of immune checkpoint inhibitors in the treatment of advanced gastric cancer: A review. 12, 0
- 16 HER2-Positive Gastroesophageal Cancers Are Associated with a Higher Risk of Brain Metastasis. **2022**, 14, 5754 0
- 15 CDH17 nanobodies facilitate rapid imaging of gastric cancer and efficient delivery of immunotoxin. **2022**, 26, 1
- 14 Surface-Engineered Extracellular Vesicles with CDH17 Nanobodies to Efficiently Deliver Imaging Probes and Chemo-Photothermal Drugs for Gastric Cancer Theragnostic. 2209393 0
- 13 OncoVee™ -MiniPDX-guided anticancer treatment for HER2-negative intermediate-advanced gastric cancer patients: A single-arm, open-label phase I clinical study. 0
- 12 Research progress of antibody-drug conjugates therapy for HER2-low expressing gastric cancer. **2023**, 29, 101624 0
- 11 Near Infrared Photoimmunotherapy: A Review of Recent Progress and Their Target Molecules for Cancer Therapy. **2023**, 24, 2655 0
- 10 Challenges and future of HER2-positive gastric cancer therapy. 13, 0
- 9 Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing. **2023**, 24, 4877 0
- 8 Clinicopathological Significance and Prognostic Role of Her2neu Protein Expression in Patients with Carcinoma Stomach: A Prospective Study from Northern India. 0
- 7 Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma: retrospective, international, multicentric AGEO study. **2023**, 26, 425-437 0
- 6 Real-world clinical outcomes of the combination of anti-PD -1 antibody, trastuzumab, and chemotherapy for HER2 -positive gastric/gastroesophageal junction cancer. 0

- 5 Separation and single-cell analysis for free gastric cancer cells in ascites and peritoneal lavages based on microfluidic chips. **2023**, 90, 104522 ○
- 4 Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers. **2023**, 15, 1845 ○
- 3 Heat shock protein 90 (HSP90) inhibitors in gastrointestinal cancer: where do we currently stand? A systematic review. ○
- 2 CircRNA: A new class of targets for gastric cancer drug resistance therapy. 29, ○
- 1 Research Progress of Targeted Combined Immunization in HER2 Positive Advanced Gastric Cancer: From Bench to Bedside. **2023**, 13, 5864-5871 ○